Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 6/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633587 | 1.00 | DGAT1 (0.47) | DGAT1PREPTP53L3MBTL1CYP19A1 | |
| SCHEMBL7304447 | 0.87 | DGAT1 (0.58) | DGAT1PREPCYP19A1MAPTALDH1A1 | |
| SCHEMBL7292707 | 0.87 | DGAT1 (0.58) | DGAT1PREPCYP19A1MAPTALDH1A1 | |
| SCHEMBL3406500 | 0.87 | DGAT1 (0.58) | DGAT1PREPCYP19A1MAPTALDH1A1 | |
| SCHEMBL30612421 | 0.87 | DGAT1 (0.58) | DGAT1PREPCYP19A1MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL7389195 | 0.85 | DGAT1 (0.56) | DGAT1PREPCYP19A1MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL7393121 | 0.85 | DGAT1 (0.56) | DGAT1PREPCYP19A1MAPTALDH1A1 | |
| SCHEMBL11461276 | 0.84 | SIGMAR1 (0.52) | TP53L3MBTL1CYP19A1 | |
| SCHEMBL8732825 | 0.83 | AKR1B1 (0.39) | DGAT1PREPTP53L3MBTL1GAA | |
| SCHEMBL7072581 | 0.82 | SLC6A1 (0.43) | DGAT1PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110183330-B | Preparation method of 5, 6-diethyl-2, 3-dihydro-1H-indene-2-amine hydrochloride | 安徽华邦药业有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-101679346-A | substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI AVENTIS | 2010-03-24 | — | — | CN | claimed |
| JP-5085999-A | — | — | None | — | — | JP | disclosed |
| EP-4142878-B1 | PYRIDINE INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4142878-B1 | PYRIDINE INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11998901-B2 | Metal complex, method for producing same, and method for producing gamma-lactam compound using same | INSTITUTE FOR BASIC SCIENCE (KR) | 2024-06-04 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4048397-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THERAPEUTIC APPLICATIONS | UNIV MICHIGAN REGENTS (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230212123-A1 | Pyridine Inhibitors of Glucosylceramide Synthase and Therapeutic Methods Using the Same | UNIV MICHIGAN REGENTS (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212123-A1 | Pyridine Inhibitors of Glucosylceramide Synthase and Therapeutic Methods Using the Same | UNIV MICHIGAN REGENTS (US) | 2023-07-06 | — | — | US | disclosed |
| US-5194437-A | Substituted with oxygen containing heterocycle, central nervous system disorders, neuroendocrine disorders | ADIR ET COMPAGNIE (FR) | 1993-03-16 | — | — | US | disclosed |
| US-5028604-A | Cognition Activators | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-02 | — | — | US | disclosed |
| EP-0372484-A2 | Condensed benzene derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1990-06-13 | — | — | EP | disclosed |
| EP-0194764-B1 | PESTICIDAL COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-07-12 | — | — | EP | disclosed |
| EP-0194764-A1 | Pesticidal compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-09-17 | — | — | EP | disclosed |
| US-4152527-A | 15-Substituted-ω-pentanorprostaglandins | PFIZER INC. (US) | 1979-05-01 | — | — | US | disclosed |
| US-4127578-A | Diene intermediates for indantetrols | E. R. SQUIBB & SONS, INC. (US) | 1978-11-28 | — | — | US | disclosed |
| US-4092318-A | HYPOTENSIVES | E. R. SQUIBB & SONS, INC. (US) | 1978-05-30 | — | — | US | disclosed |
| US-4044040-A | HYPERTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | DGAT1 2328/4885PREP 3481/4885TP53 4/4885 |
| US-11998901-B2 | Metal complex, method for producing same, and method for producing gamma-lactam compound using same | COASY, NOTUM, MRPL21 | DGAT1 1967/4885PREP 512/4885TP53 4530/4885 |
| US-20230212123-A1 | Pyridine Inhibitors of Glucosylceramide Synthase and Therapeutic Methods Using the Same | GBA1, GAA, GBA2 | DGAT1 292/4885PREP 180/4885TP53 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.